(jofem.org) The best-case signal: modest weight loss in a shorter trial A frequently cited 12-week randomized trial result (as summarized in reviews) reported: ~2.6 kg average loss with AOD-9604 1 mg/day vs ~0.8 kg with placebo (PMC) This is the kind of result that can be statistically meaningful, clinically modest, and very sensitive to study design (diet, activity, baseline metabolic status, adherence)
Published incidence figures for B12 deficiency after sleeve gastrectomy range from 0% to over 36%, with deficiency sometimes not appearing until two years after surgery (3)
The blend is not approved for human use Tesamorelin alone is FDA-approved as EGRIFTA for HIV-associated lipodystrophy, while Ipamorelin is not FDA-approved for any indication
conducted a meta-analysis to estimate whether NAFLD patients have higher serum levels of homocysteine than healthy controls 24
Marichela Sepe (DICEA-SAPIENZA UNIVERSITA' DI ROMA-ISMED CNR) 215 Collaborative GIS for Sustainable Waste Management
Mistake 3: Ignoring peptide receptor competition
%20(1).png)
